Cognitive aging is a major source of disability in an increasingly aging population. The paucity of effective treatments for cognitive aging disorders instigates a need for further research into novel therapeutic possibilities. Glutamate mediated excitotoxicity in neuropsychiatric disorders has been shown to cause significant cerebral damage. Mild cognitive impairment (MCI) is a transitional stage between normal aging and Alzheimer's disease and it should be an area of focus for early intervention in order to prevent or at least retard neuropathological progression that will lead to irreversible neuronal loss and dementia. Pathological studies have shown that subjects with MCI display a paradoxical elevation in glutamatergic presynaptic boutons. Riluzole, a glutamate modulator agent that is a provenly safe medication and has not yet been used in cognitive aging disorders, will be tested in MCI patients with cognitive complaints. Cognitive functional changes along with in vivo biomarkers such as MR spectroscopy and cerebral perfusion studies will be evaluated.